James F. Young - Dec 31, 2021 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role: Director
Signature: /s/ John A. Herrmann III, Attorney-in-Fact
Stock symbol: NVAX
Transactions as of: Dec 31, 2021
Transactions value $: -$444,601
Form type: 4
Date filed: 1/4/2022, 04:04 PM
Previous filing: Jul 6, 2021
Next filing: Apr 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVAX	Common Stock	Options Exercise	$96K	+3.75K	+4.99%	$25.60	78.8K	Dec 31, 2021	Direct
transaction	NVAX	Common Stock	Sale	-$541K	-3.75K	-4.76%	$144.16^*	75.1K	Dec 31, 2021	Direct	F1
holding	NVAX	Common Stock						1.5K	Dec 31, 2021	By spouse	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NVAX	Stock Option (Right to Buy)	Options Exercise	$0	-3.75K	-100%	$0.00^*	0	Dec 31, 2021	Common Stock	3.75K	$25.60	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.1004 to $144.37, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F2	The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Content

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.1004 to $144.37, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.